Drug Database
Back to search

Netherlands· NL-8e836196640f

Inluriyo 200 mg filmomhulde tabletten

A medicinal product containing imlunestranttosilaat, registered in Netherlands by Eli Lilly Nederland B.V..

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedInluriyo 200 mg filmomhulde tablettenATC—REGISTER NO.NL-8e836196640fPACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about imlunestranttosilaatAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

The record

At a glance

CBG-MEB (Netherlands)
Active substance
IMLUNESTRANTTOSILAAT
Manufacturer
Eli Lilly Nederland B.V.
Country
Netherlands (NL)
ATC code
—
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/25/2003

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Imlunestranttosilaat in 10 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All imlunestranttosilaat products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Inluriyo
  • Liechtenstein · Inluriyo
  • Norway · Inluriyo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ee3c3cf8-c27a-40d9-9344-a50c222bca2d
GET /v1/drugs/ee3c3cf8-c27a-40d9-9344-a50c222bca2d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/inluriyo-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": null,
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp134378",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "HYPROLOSE (E 463)",
    "MACROGOL 3350",
    "MAGNESIUMSTEARAAT (E 470b)",
    "POLYVINYLALCOHOL (E 1203)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "IMLUNESTRANTTOSILAAT"
  ],
  "leaflet_url": null,
  "authorised_at": "2026/01/09",
  "procedure_number": "EMEA/H/C/006184",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/25/2003",
  "additional_monitoring": "Y"
}
API referenceMCP serverPlans

See everything about imlunestranttosilaat.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console